Kaplan-Meier overall survival analysis for patients with ccRCC related to clinicopathological and molecular data. (A) TNM classification. (B) ISUP grade. (C) SHH mRNA expression. (D) SMO mRNA expression. (E) SUFU mRNA expression. (F) GLI2 mRNA expression. (G) GLI3 mRNA expression. (H) GLI1 mRNA expression. (I) PTCH1 mRNA expression. (J) BCL2 mRNA expression. (K) MYC mRNA expression. (L) CCND1 mRNA expression. (M) VEGFA mRNA expression. Cut-off values for increased and decreased expression were determined using the median expression value of each gene in the control samples. The log-rank (Mantel-Cox) test was applied. SHH, sonic hedgehog ligand; SMO, smoothened; SUFU, suppressor of fused homolog; GLI1,2,3, glioma-associated zinc finger protein 1, 2, 3; PTCH1, patched 1; CCND1, cyclin D1; VEGFA, vascular endothelial growth factor A; ccRCC, clear cell renal cell carcinoma; qPCR, quantitative PCR; ISUP, International Society of Urological Pathology.